The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors.
Tara C. Gangadhar
No relevant relationships to disclose
Jan Hendrik Beumer
No relevant relationships to disclose
Igor Espinoza-Delgado
No relevant relationships to disclose
Bean N. Anyang
No relevant relationships to disclose
Sanja Karovic
No relevant relationships to disclose
Manish Sharma
No relevant relationships to disclose
Yujia Wen
No relevant relationships to disclose
Linda A. Janisch
No relevant relationships to disclose
Hedy Lee Kindler
Consultant or Advisory Role - Merck
Research Funding - Merck
Rita Nanda
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Mark J. Ratain
No relevant relationships to disclose
Michael L. Maitland
No relevant relationships to disclose